Pay in 4 interest-free payments of $6.56 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Safety & Regulatory Status PT-141: FDA-Approved PT-141 (bremelanotide) completed the full FDA approval pathway: Two Phase III trials (RECONNECT) with 1,267 women Established safety profile over 24-week treatment periods Known drug interactions (minimal low CYP enzyme metabolism) Maximum frequency: one dose per 24 hours MT-2: Unregulated MT-2 has only completed Phase I clinical trials (safety/tolerability in small groups): No Phase II or III efficacy/safety data for tanning All available product is unregulated research chemical No standardized manufacturing or quality control Purity varies significantly between sources This regulatory gap is the single biggest difference in risk profile between these peptides
Reported side effects are generally mild and may include nausea, dizziness, headache, or injection site irritation
Jardim-Messeder D, Zamocky M, Sachetto-Martins G, Margis-Pinheiro M (2022) Chloroplastic ascorbate peroxidases targeted to stroma or thylakoid membrane: the chicken or egg dilemma
(2022) 9:1019120/BIBTEX
This likely requires (1) commercialization costs to come down, (2) Contract Commercial Orgs (CCOs) to be much more effective, and (3) improved ability to forecast drug sales, but I believe this would allow the industry to take on a meaningfully different shape than today
US$ 28.17
US$ 20.00
US$ 28.38
